Unknown

Dataset Information

Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma.


ABSTRACT:

Background

CD4+ T-cell lymphocytopenia and immune dysfunction are factors that drive the onset and persistence of Kaposi sarcoma (KS) in people with (PWH) and without HIV. Standard chemotherapy agents for KS can contribute to increasing CD4+ T cell lymphocytopenia. IL-7 is a cytokine that is essential in T-cell development, proliferation and homeostasis. In PWH, IL-7 administration leads to increased numbers of circulating central memory and naïve T-cell phenotypes.

Methods

In this multicenter phase I study with a 3+3 dose escalation design, participants with KS with or without HIV received up to four intramuscular injections of IL-7 (NT-I7) every 9 weeks. The primary endpoint of the study was to evaluate safety over three escalating dose levels (DL) of

SUBMITTER: Ramaswami R 

PROVIDER: S-EPMC11804200 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature